18F-FDOPA PET/CT Findings in a Patient With Primary Cerebral Amyloidoma

Clin Nucl Med. 2020 Apr;45(4):e206-e207. doi: 10.1097/RLU.0000000000002959.

Abstract

Amino acid PET, including F-FDOPA, is recommended for initial characterization, delineation of tumor extent, and follow-up of gliomas because of its high diagnostic performances. F-FDOPA accumulates inside tumor cells via the L-type amino acid transporter 1 (LAT1) whose expression is increased in gliomas. We report here a case of a histopathologically proven brain amyloidoma that was first addressed for a suspected glioma. Congo red staining showed scattered extracellular deposits of amyloid and immunohistochemistry-highlighted LAT1 expression, explaining the high F-FDOPA uptake found in this lesion. This case indicates that differential diagnosis of the F-FDOPA uptake in brain lesions should include amyloidoma.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Amyloidosis / diagnostic imaging*
  • Brain Neoplasms / diagnostic imaging*
  • Diagnosis, Differential
  • Dihydroxyphenylalanine / analogs & derivatives
  • Female
  • Glioma / diagnostic imaging*
  • Humans
  • Positron Emission Tomography Computed Tomography*
  • Radiopharmaceuticals

Substances

  • Radiopharmaceuticals
  • fluorodopa F 18
  • Dihydroxyphenylalanine